---
title: "Horizon Space Acquisition II Corp. FY 2025: Net income $1.81M — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282092967.md"
description: "Horizon Space Acquisition II Corp. reported a net income of $1.81M for FY 2025, a significant increase from $143K in FY 2024, as per its 10-K summary. The company, which had no prior commercial operations, is transitioning to an operating public company following a merger with SL Bio Ltd. IPO proceeds of $69M are in trust for the acquisition. The company has secured short-term trust deposits to extend its combination period and is preparing for a Nasdaq listing after the merger's completion."
datetime: "2026-04-08T20:25:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282092967.md)
  - [en](https://longbridge.com/en/news/282092967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282092967.md)
---

# Horizon Space Acquisition II Corp. FY 2025: Net income $1.81M — 10-K Summary

Horizon Space Acquisition II Corp. reported net income of $1.81M for fiscal 2025, up from $143K in fiscal 2024, according to its 10-K summary. The company had no commercial operations or revenues prior to completing a business combination and continues to prepare for its transition to an operating public company.

**Financial Highlights**

-   **Net income:** $1.81M for FY 2025, compared with $143K in FY 2024.
-   **Diluted earnings per share:** Not disclosed in the cited sections.
-   **Revenue:** Not disclosed in the cited sections.

**Business Highlights**

-   **Business combination:** Entered a definitive agreement to merge with SL Bio Ltd., advancing from a SPAC to an operating company under the combined public company (PubCo).
-   **Capital deployment:** IPO proceeds of $69M were placed in trust to fund the acquisition and post-combination operations.
-   **Operational status:** Prior to the combination the company had no commercial operations or revenues; activities were focused on target identification and due diligence.
-   **Public listing transition:** Units were separated for trading (HSPT/HSPTR); PubCo ordinary shares are expected to list on Nasdaq after closing.
-   **Extension & continuity plans:** The company secured multiple short-term trust deposits and amendments to extend its combination period and support completion of the transaction.

Original SEC Filing: Horizon Space Acquisition II Corp. \[ HSPT \] - 10-K - Apr. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [HSPT.US](https://longbridge.com/en/quote/HSPT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [MBIO.US](https://longbridge.com/en/quote/MBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BLFS.US](https://longbridge.com/en/quote/BLFS.US.md)
- [SAVU.US](https://longbridge.com/en/quote/SAVU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [MindBio Therapeutics Corp. (CSE: MBIO) Harnesses Key AI, Voice Analysis to Offer Impairment Solution](https://longbridge.com/en/news/286418745.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)